Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03132922 · OUTCOME

Time to Response (TTR)

MAGE-A4ᶜ¹º³²T for Multi-Tumor · Source last updated 2026-06-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Weeks
Interval / dispersion
95% Confidence Interval
Time frame
From afamitresgene autoleucel infusion until first documented confirmed CR or PR

What was measured

TTR was defined as the interval between the date of the first T-cell infusion and the earliest date of the first documented confirmed CR or confirmed PR.

Analysis population: Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel achieving CR or PR.

Groups in this outcome

Afamitresgene Autoleucel, Group 1

Participants who received afamitresgene autoleucel 0.1x10\^9 transduced cells

Afamitresgene Autoleucel, Group 2

Participants who received afamitresgene autoleucel 0.5-1.2x10\^9 transduced cells

Afamitresgene Autoleucel, Group 3 + Expansion

Participants who received afamitresgene autoleucel 1.2-10x10\^9 transduced cells

Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel

Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Afamitresgene Autoleucel, Group 10
Afamitresgene Autoleucel, Group 20
Afamitresgene Autoleucel, Group 3 + Expansion9
Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel1

Reported measurements

Source class 1
Values in Weeks · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Afamitresgene Autoleucel, Group 3 + Expansion6.4Not reported6.14324.143Not reported
Low Dose Radiation (LDR) in Combination With Afamitresgene AutoleucelNANot reportedNANAOnly one participant in this arm achieved a response. With a single observation event, a median time to response and confidence interval cannot be estimated.
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG002
        lower Limit
        6.143
        upper Limit
        24.143
        value
        6.4
      2. comment
        Only one participant in this arm achieved a response. With a single observation event, a median time to response and confidence interval cannot be estimated.
        group Id
        OG003
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    3. group Id
      OG002
      value
      9
    4. group Id
      OG003
      value
      1
    units
    Participants
description
TTR was defined as the interval between the date of the first T-cell infusion and the earliest date of the first documented confirmed CR or confirmed PR.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants who received afamitresgene autoleucel 0.1x10\^9 transduced cells
    id
    OG000
    title
    Afamitresgene Autoleucel, Group 1
  2. description
    Participants who received afamitresgene autoleucel 0.5-1.2x10\^9 transduced cells
    id
    OG001
    title
    Afamitresgene Autoleucel, Group 2
  3. description
    Participants who received afamitresgene autoleucel 1.2-10x10\^9 transduced cells
    id
    OG002
    title
    Afamitresgene Autoleucel, Group 3 + Expansion
  4. description
    Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion.
    id
    OG003
    title
    Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel
param Type
MEDIAN
population Description
Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel achieving CR or PR.
reporting Status
POSTED
time Frame
From afamitresgene autoleucel infusion until first documented confirmed CR or PR
title
Time to Response (TTR)
type
SECONDARY
unit Of Measure
Weeks

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice